open access

Vol 47, No 3 (2016)
Prace oryginalne / Original research articles
Published online: 2016-07-01
Submitted: 2016-07-12
Get Citation

Retrospective analysis of nilotinib and dasatinib efficacy in second line treatment of chronic myeloid leukemia in Polish hematological centers

Anna Stępień1, Krzysztof Jamroziak2, Tomasz Sacha3, Dorota Link-Lenczowska3, Izabela Florek3, Witold Prejzner4, Zofia Specht-Szwoch5, Małgorzata Całbecka6, Marcin Rymko6, Marek Dudziński7, Paulina Wieszczy8, Krzysztof Warzocha2, Janina Góra-Tybor2
DOI: 10.1016/j.achaem.2016.08.002
·
Acta Haematol Pol 2016;47(3):219-225.
Affiliations
  1. Pracownia Immunologii Klinicznej, Transplantacyjnej i Genetyki, Wojewódzki Szpital Specjalistyczny im. M. Kopernika w Łodzi, Łódź, Polska
  2. Klinika Hematologii, Instytut Hematologii i Transfuzjologii, Warszawa, Polska
  3. Klinika Hematologii Uniwersytetu Jagiellońskiego, Kraków, Polska
  4. Klinika Hematologii i Transplantologii, Gdański Uniwersytet Medyczny, Gdańsk, Polska
  5. Regionalne Centrum Onkologii, Gdańsk, Polska
  6. Klinika Hematologii, Miejski Szpital Specjalistyczny im. M. Kopernika w Toruniu, Toruń, Polska
  7. Klinika Hematologii, Kliniczny Szpital Wojewódzki nr 1 im. F. Chopina, Rzeszów, Polska
  8. Klinika Gastroenterologii, Hepatologii i Onkologii Klinicznej, Centrum Medycznego Kształcenia Podyplomowego, Warszawa, Polska

open access

Vol 47, No 3 (2016)
Prace oryginalne / Original research articles
Published online: 2016-07-01
Submitted: 2016-07-12

Abstract

Until now, there has been no randomized study directly comparing the activity of second-generation BCR-ABL tyrosine kinase inhibitors (TKI-2G) nilotinib and dasatinib in chronic myeloid leukemia (CML). The aim of our study was to retrospectively analyze efficacy of nilotinib and dasatinib in the real life setting of CML with resistance or intolerance of imatinib. Of 108 included patients treated in polish hematology centers, 75 received dasatinib and 33 patients received nilotinib. Rates of complete cytogenetic response (CCyR) did not differ between the two groups of patients. After six months of therapy, CCyR was achieved in 34.7% of patients treated with dasatinib and 38.7% treated with nilotinib (p=0.86), while after 12 months, the CCyR rates were 60.0% and 77.0% in dasatinib and nilotinib groups, respectively (p=0.11). Moreover, we have not observed any significant difference in the probability of progression-free survival (p=0.89) or overall survival (p=0.99) between patients treated with these two TKI-2G. In conclusion, the results of our analysis indicate that nilotinib and dasatinib have comparable and satisfactory efficacy in the treatment of CML patients refractory or intolerant to imatinib. Our findings support current strategy of choice of IKT-2G according to drug toxicity profile and risk of specific adverse events in an individual patient.

Abstract

Until now, there has been no randomized study directly comparing the activity of second-generation BCR-ABL tyrosine kinase inhibitors (TKI-2G) nilotinib and dasatinib in chronic myeloid leukemia (CML). The aim of our study was to retrospectively analyze efficacy of nilotinib and dasatinib in the real life setting of CML with resistance or intolerance of imatinib. Of 108 included patients treated in polish hematology centers, 75 received dasatinib and 33 patients received nilotinib. Rates of complete cytogenetic response (CCyR) did not differ between the two groups of patients. After six months of therapy, CCyR was achieved in 34.7% of patients treated with dasatinib and 38.7% treated with nilotinib (p=0.86), while after 12 months, the CCyR rates were 60.0% and 77.0% in dasatinib and nilotinib groups, respectively (p=0.11). Moreover, we have not observed any significant difference in the probability of progression-free survival (p=0.89) or overall survival (p=0.99) between patients treated with these two TKI-2G. In conclusion, the results of our analysis indicate that nilotinib and dasatinib have comparable and satisfactory efficacy in the treatment of CML patients refractory or intolerant to imatinib. Our findings support current strategy of choice of IKT-2G according to drug toxicity profile and risk of specific adverse events in an individual patient.

Get Citation

Keywords

Chronic myeloid leukemia; Imatinib resistance; Nilotinib; Dasatinib

About this article
Title

Retrospective analysis of nilotinib and dasatinib efficacy in second line treatment of chronic myeloid leukemia in Polish hematological centers

Journal

Acta Haematologica Polonica

Issue

Vol 47, No 3 (2016)

Pages

219-225

Published online

2016-07-01

DOI

10.1016/j.achaem.2016.08.002

Bibliographic record

Acta Haematol Pol 2016;47(3):219-225.

Keywords

Chronic myeloid leukemia
Imatinib resistance
Nilotinib
Dasatinib

Authors

Anna Stępień
Krzysztof Jamroziak
Tomasz Sacha
Dorota Link-Lenczowska
Izabela Florek
Witold Prejzner
Zofia Specht-Szwoch
Małgorzata Całbecka
Marcin Rymko
Marek Dudziński
Paulina Wieszczy
Krzysztof Warzocha
Janina Góra-Tybor

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl